Key result
This editorial highlights recent advances in vascular medicine, including temporal trends in aortic dissection, novel molecular targets for aneurysms, and the vascular toxicity of e-cigarettes.
Answers are grounded in this paper and cite their sources.
This editorial highlights recent advances in vascular medicine, including the epidemiology of aortic dissection, molecular mechanisms of aneurysm formation, the vascular toxicity of e-cigarettes, and potential gene therapies for atherosclerosis.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. Cardiologists commonly focus on the heart, but cardiovascular medicine is more than that: the vessels are important as well. Acute aortic syndromes are a major cause of premature death1,2 and deserve appropriate attention of physicians and scientists alike in order to understand the mechanisms and predictors of dissection and rupture.3 Of note, like coronary disease4 and heart failure,5,6 diseases of the aorta have pronounced sex differences, as outlined in the article ‘Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years’ by Christian Smedberg and colleagues from the Karolinska Institutet in Stockholm, Sweden.7 During the study period between 2002 and 2016, a total of 8057 patients in Sweden were diagnosed with aortic dissection, identified from the National Patient Register and the Cause of Death Register. Of those, 71% were hospitalized, whereas 29% died without hospital stay. The annual incidence was 7.2 per 100 000, with 9.1 in men and 5.4 in women, and a decreasing trend over time in men. Within the first 14 days after onset, 32% underwent surgical repair. The proportion of surgically treated patients increased between 2002–2006 and 2012–2016 from 27% to 35% (Figure 1). In hospitalized patients, 30-day mortality decreased in the same periods from 26% to 21%. Long-term mortality also decreased by 26%. Women had higher 30-day mortality than men after acute repair; a sex difference. Thus, there is a higher incidence of aortic dissection than previously suspected, but a decreasing incidence in men. Surgical therapy is used increasingly and with more favourable outcome, but is less frequently offered to elderly patients. The sex differences regarding both incidence and outcome require attention, as outlined in an Editorial by Kim Eagle and Nicole Bhave from the University of Michigan Medical Center in Ann Arbor, USA.8 This large population-based register study of over 8000 patients with aortic dissection demonstrates a higher incidence than earlier described, an increase in surgical management and improved outcome (from Smedberg C, Steuer J, Leander K, Hultgren R. Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years. See pages 2430–2438). This large population-based register study of over 8000 patients with aortic dissection demonstrates a higher incidence than earlier described, an increase in surgical management and improved outcome (from Smedberg C, Steuer J, Leander K, Hultgren R. Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years. See pages 2430–2438). The understanding of the molecular mechanisms of aortic dissection is still limited. Thus, the article ‘Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype’ by Feng Xu and colleagues from the Shandong University Qilu Hospital in Jinan, China is greatly welcomed.9 The authors remind us that for this life-threatening disorder, pharmacotherapeutic remedies are lacking. Aldehyde dehydrogenase 2 (ALDH2) polymorphisms are linked with risk factors for the disease such as hypertension, atherosclerosis, and hypercholesterolaemia. Therefore, the authors conducted two case–control studies with 307 patients with aortic aneurysm or dissection, and 399 healthy controls. Subjects carrying a mutant ALDH2 gene had a 50% reduced risk of aortic aneurysm or dissection compared with those with wild-type alleles. Using animal models, inhibition of ALDH2 was found to retard the development of aortic aneurysm and dissection. Mechanistically, ALDH2 inhibition ablated the vascular smooth muscle cell (VSMC) phenotypical switch through interaction with myocardin, a determinant of the contractile phenotype. Using microarray and bioinformatics analyses, ALDH2 deficiency was found to down-regulate miR-31-5p, which further altered the myocardin mRNA level. Gain- and loss-of-function studies verified that miR-31-5p significantly repressed myocardin levels and aggravated the VSMC phenotypical switch and formation of an aortic aneurysm or dissection, an effect blunted by ALDH2 inhibition. Thus, ALDH2 mutation or inhibition down-regulates miR-31-5p levels, while promoting contractile genes downstream of myocardin in the context of high angiotensin II levels in primary human VSMCs. Through these pathways, ALDH2 deficiency is associated with a lower risk of aortic aneurysm and dissection in patients and mice. These novel findings suggest that ALDH2 and miR-31-5p might be novel targets for preventive therapies, as further discussed in an Editorial by Elena Aikawa from the Harvard Medical School in Boston, Massachusetts.10 Obesity has become a real epidemic and is associated with unfavourable cardiovascular outcomes.11 It is, however, difficult to manage. As a result, it is currently even treated with surgery.12,13 Obesity is a risk factor not only for diabetes and coronary disease, but also for abdominal aortic aneurysms, as it is associated with activation of inflammatory pathways. The cytokine interleukin-18 (IL-18) has two receptors, i.e. the IL-18 receptor and the Na–Cl co-transporter. In human and mouse abdominal aortic aneurysm lesions, IL-18 co-localizes with its receptors at regions rich in adipocytes, suggesting a role of adipocytes in promoting IL-18 actions, as further evaluated in the article ‘Adipocytes promote interleukin-18 binding to its receptors during abdominal aortic aneurysm formation in mice’ by Guo-Ping Shi and colleagues from the Brigham and Women’s Hospital in Boston, Massachusetts.14 Murine abdominal aortic aneurysm development requires both receptors. In mouse abdominal aortic aneurysm lesions, IL-18 binding to these receptors increased adjacent to perivascular adipose tissue. 3T3-L1 adipocytes enhanced IL-18 binding to macrophages, aortic smooth muscle, and endothelial cells by inducing expression of both IL-18 receptors. Adipocytes also enhanced the expression of IL-18 and the IL-18 receptor in T cells and macrophages, as well as aneurysm-pertinent protease expression by macrophages and smooth muscle cell apoptosis. Perivascular implantation of adipose tissue from either diet-induced obese mice or lean mice, but not that from ob/ob–/– mice, exacerbated aneurysm development. Adipocyte leptin and fatty acid binding-protein 4 were essential in promoting IL-18 binding to macrophages and possibly other inflammatory and vascular cells by inducing their expression of IL-18, IL-18 receptor, and Na-Cl co-transporter. Thus, IL-18 uses both its receptor and and the Na–Cl co-transporter to promote aneurysm formation. Lesion adipocyte and perivascular adipose tissue contribute to the pathogenesis by releasing leptin and fatty acid-binding protein 4 to active this inflammatory pathway. The clinical perspective of these findings is discussed in an Editorial by Lars Maegdefessel and colleagues from the Karolinska Institutet in Stockholm, Sweden.15 Smoking is a major risk factor not only for coronary artery disease, but also for aneurysm formation and rupture. Smoking cessation is challenging, as it is linked to genetic factors16 and is addictive in its own right. Electronic cigarettes have been marketed as a ‘healthy’ alternative to cigarettes and as effective for smoking cessation. In their article entitled ‘Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2)’, Thomas Münzel and colleagues from the Johannes Gutenberg Universität in Mainz, Germany evaluate these claims.17 They remind us that e-cigarettes can induce oxidative stress and vascular dysfunction, although the mechanisms are still unclear. Acute e-cigarette smoking produced a 27% impairment of endothelial function in chronic smokers as determined by flow-mediated dilation. In mice, e-cigarette vapour without nicotine had more detrimental effects on oxidative stress, inflammation, lipid peroxidation, and eventually endothelial function than vapour containing nicotine. These effects of e-cigarette vapour were largely absent in mice lacking phagocytic NADPH oxidase or NOX-2. In vitro blood vessel incubation with the e-cigarette product acrolein, a reactive aldehyde, recapitulated the NOX-2-dependent effects of e-cigarette vapour (Figure 2). Thus, e-cigarette vapour exposure increases vascular and cerebral oxidative stress by a NOX-2-dependent mechanism via the toxic aldehyde acrolein. As such, e-cigarettes might induce adverse cardiovascular and cerebrovascular effects, which is concerning given their increasing use amongst the youth. This is further explored in an Editorial by Tomasz Guzik and colleagues from the University of Glasgow in the UK.18 E-cigarette vaping induced cardiovascular complications are prevented by pharmacological ET-1 receptor blockade and FOXO-3 activation. Central scheme: proposed mechanisms of E-cigarette mediated cerebro/cardiovascular complications from studies in mice. The described adverse effects are also operative in the disease development and progression of classical cerebro/cardiovascular diseases such as stroke, atherosclerosis, hypertension, and coronary artery disease. Light blue colour represents pharmacological/genetic interventions (from Kuntic M, Oelze M, Steven S, Kröller-Schön S, Stamm P, Kalinovic S, Frenis K, Vujacic-Mirski K, Jimenez MTB, Kvandova M, Filippou K, Al Zuabi A, Brückl V, Hahad O, Daub S, Varveri F, Gori T, Huesmann R, Hoffmann T, Schmidt FP, Keaney JF, Daiber A, Münzel T. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). See pages 2472–2483). E-cigarette vaping induced cardiovascular complications are prevented by pharmacological ET-1 receptor blockade and FOXO-3 activation. Central scheme: proposed mechanisms of E-cigarette mediated cerebro/cardiovascular complications from studies in mice. The described adverse effects are also operative in the disease development and progression of classical cerebro/cardiovascular diseases such as stroke, atherosclerosis, hypertension, and coronary artery disease. Light blue colour represents pharmacological/genetic interventions (from Kuntic M, Oelze M, Steven S, Kröller-Schön S, Stamm P, Kalinovic S, Frenis K, Vujacic-Mirski K, Jimenez MTB, Kvandova M, Filippou K, Al Zuabi A, Brückl V, Hahad O, Daub S, Varveri F, Gori T, Huesmann R, Hoffmann T, Schmidt FP, Keaney JF, Daiber A, Münzel T. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). See pages 2472–2483). Ageing and longevity genes are likely to play a crucial role in cardiovascular disease.19 Myocardial infarction and stroke are particularly prevalent among the elderly. In their Basic Science article ‘Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism’ Carmine Vecchione and colleagues from the University of Saleno in Baronissi, Italy assessed the therapeutic effect of longevity-associated variant LAV-BPIFB4 gene therapy on atherosclerosis.20 ApoE−/− mice fed a high-fat diet were randomly allocated to receive LAV-BPIFB4, wild-type BPIFB4, or an empty adeno-associated viral vector. LAV-BPIFB4 gene therapy rescued endothelial function of mesenteric and femoral arteries from ApoE−/− mice; this effect was blunted by AMD3100, a CXC chemokine receptor type 4 (CXCR4) inhibitor. LAV-BPIFB4-treated mice showed a CXCR4-mediated shift in the balance between Ly6Chigh/Ly6Clow monocytes and M2/M1 macrophages, along with decreased T-cell proliferation and elevated circulating levels of interleukins IL-23 and IL-27. In vitro conditioning with LAV-BPIFB4 protein of macrophages from atherosclerotic patients resulted in a CXCR4-dependent M2 polarization phenotype. Furthermore, LAV-BPIFB4 treatment of arteries explanted from atherosclerotic patients increased the release of athero-protective IL-33, while inhibiting the release of proinflammatory IL-1β, inducing endothelial nitric oxide synthase (eNOS) phosphorylation and restoring endothelial function. Finally, significantly lower plasma BPIFB4 was detected in patients with pathological carotid stenosis than in controls. Thus, transfer of the longevity-associated variant of BPIFB4 reduces atherosclerosis and shifts macrophages towards an M2-resolving phenotype via CXCR4, thus opening up novel therapeutic possibilities in cardiovascular disease, as further discussed in an Editorial by Giovanni Camici and Luca Liberale from the University of Zurich in Switzerland.21 The issue is also complemented by various Discussion Forum contributions. In a piece entitled ‘Sleep patterns, genetic susceptibility, and incident cardiovascular disease: the role of miRNAs’ Salvatore Patanè from the Cardiologia Ospedale San Vincenzo-Taormina (Me) Azienda Sanitaria Provinciale di Messina comments on the recent publication entitled ‘Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK Biobank participants’ by Lu Qi and colleagues from the Tulane University School of Public Health and Tropical Medicine in New Orleans, USA.22,23 Qi responds in a separate comment.24 In a contribution entitled ‘Obstructive sleep apnoea and inflammation in age-dependent cardiovascular disease’ John Elsby Sanderson and colleagues from the Capital Medical University Affiliated Anzhen Hospital in Beijing, China comment on the recent contribution entitled ‘Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease’ by Giovanni Camici and colleagues from the University of Zurich.19,25 Camici et al. respond to Sanderson in a separate comment.26 The editors hope that this issue of the European Heart Journal will be of interest to its readers. With thanks to Amelia Meier-Batschelet for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2020) conducted an editorial in Vascular diseases (aortic dissection, aneurysm, atherosclerosis). This editorial highlights recent advances in vascular medicine, including temporal trends in aortic dissection, novel molecular targets for aneurysms, and the vascular toxicity of e-cigarettes.
Synapse has enriched 10 related papers. Consider them for comparative context: